VERA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Vera Therapeutics Inc (VERA) is not a strong buy at the moment for a beginner investor with a long-term focus. While there are positive analyst ratings and price target upgrades, the technical indicators and financial performance do not suggest an immediate entry point. The lack of significant trading trends, recent news, and proprietary trading signals further supports a hold stance.
The MACD histogram is -0.264, below 0, and negatively contracting, indicating a bearish trend. RSI is at 43.258, in the neutral zone, suggesting no clear momentum. Moving averages are converging, and the stock is trading near its support level (S1: 41.458). Overall, the technical indicators are neutral to slightly bearish.
Analysts have raised price targets significantly, with Goldman Sachs increasing the target to $95 and BofA to $66, reflecting optimism about Vera's lead drug and its market potential. The FDA approval of a competitor's drug has also positively influenced market assumptions for Vera.
The stock's technical indicators are neutral to bearish, with no clear upward momentum. Financial performance remains weak, with no revenue and a significant net loss (-$80.29M in Q3 2025). Additionally, there are no recent news or significant trading trends from hedge funds or insiders.
In Q3 2025, Vera reported no revenue growth (0% YoY) and a net loss of $80.29M, though this was a 72.18% improvement YoY. EPS improved to -1.26, up 48.24% YoY, but the company remains unprofitable.
Analysts are optimistic about Vera, with multiple price target upgrades in December 2025. Goldman Sachs raised its target to $95, BofA to $66, and JPMorgan to $96, citing higher market potential for Vera's lead drug and improved financial positioning. However, JPMorgan also slightly lowered its target from $99 to $96.
